1384097-59-9

Upstream product

• 118-41-2 Eudesmic acid 
• 3291-03-0 3,4,5-trimethoxybenzohydrazide 
• 6178-44-5 ethyl 3,4,5-trimethoxybenzoate 
• 31821-78-0 4-amino-3-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-5(4H)-thione 
• 100-52-7 benzaldehyde 

Downstream Products

• 1384097-61-3 (E)-N-benzylidene-3-(benzylthio)-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-4-amine 
• 1384097-63-5 (E)-N-benzylidene-3-(2-chlorobenzylthio)-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-4-amine 
• 1384097-69-1 ethyl 2-(6-phenyl-3-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl) acetate 
• 1384097-68-0 2-(6-phenyl-3-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)-1-p-tolylethanone 
• 1384097-62-4 (E)-N-benzylidene-3-(4-fluorobenzylthio)-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-4-amine 

Relevant academic research and scientific papers

Synthesis and cytotoxicity of 3,4-disubstituted-5-(3,4,5-trimethoxyphenyl)- 4H-1,2,4-triazoles and novel 5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazole derivatives bearing 3,4,5-trimethoxyphenyl moiety

A series of 3,4-disubstituted-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazoles and some novel 5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles bearing 3,4,5-trimethoxyphenyl moiety were synthesized and screened for their anticancer activity. The preliminary bioassay results indicated that compounds 14 and 16 showed much stronger cytotoxicity than Doxorubicin against HepG2 cell lines with IC50 values of 0.58 and 3.17 μM, respectively. Meanwhile compound 16 also exhibited a broad spectrum of antitumor activity against MCF-7 and MKN45 with IC50 values of 10.92 and 13.79 μM, respectively.